Compare IDEXX Laboratories, Inc. (IDXX) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Opendoor Technologies Inc — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Opendoor Technologies Inc trades at $4.48 (market cap $4.29B). The key difference: IDEXX Laboratories, Inc. is far larger — about 10.4× Opendoor Technologies Inc's market cap, and Opendoor Technologies Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | OPEN | |
|---|---|---|
Market Cap | $44.48B | $4.29B |
Sector | Health | Real Estate |
52-Week High | $766.68 | $10.52 |
52-Week Low | $520.87 | $1.84 |
Enterprise Value | $45.38B | $4.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Opendoor Technologies (OPEN) trades at $4.415, down 1.89% on the day, reflecting ongoing market skepticism despite recent operational improvements. The stock shows a bearish technical trend with mixed oscillators, while fundamentals reveal persistent losses with a -35.25% net income margin and negative ROE of -173.61%. Revenue has declined from $15.6B in 2022 to $4.37B in 2025, though cash flow turned positive in 2025 at $538M. Recent news highlights CEO focus on housing market challenges and India operations closure to prioritize AI integration.
The outlook remains cautious with high debt and profitability concerns offset by low P/S valuation and analyst 'Hold' consensus. Key risks include interest rate sensitivity and execution of the Opendoor 2.0 model, while potential upside hinges on margin stabilization and seasonal housing rebounds. Investors face a high-risk, speculative opportunity amid structural shifts in real estate tech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
